美女免费一级视频在线观看

Eli Lilly’s shares rose on Wednesday morning after the pharma giant released a study that found its weight loss drug Zepbound helped patients shed more weight than Novo Nordisk’s Wegovy in the first randomized controlled clinical trial comparing the two drugs. 

The drugmaker said that patients who took Zepbound lost on average around 20% of their weight compared to the 13.7% they lost with Wegovy. As two of the most popular GLP-1 offerings, both drugs need to be injected weekly. 

Lilly also said that Zepbound beat Wegovy in five different key endpoints after 72 weeks of taking the drugs. Nearly one-third of people who took Zepbound achieved at least 25% weight loss compared to 16% of people taking Wegovy after one year. 

Lilly’s randomized clinical trial included 751 participants across the United States and Puerto Rico, where participants were administered the maximum tolerated dose of both drugs. 

Previous independent studies have also indicated similar results – that Zepbound helps patients lose more weight than Wegovy after a year of continual use. 

Plus, a higher percentage of participants were shown to discontinue the use of Wegovy compared to Zepbound in Phase 3 clinical trials initiated by the individual drugmakers. 

The results from the study have yet to be peer-reviewed and will be presented at medical meetings next year. 

Both Zepbound and Wegovy target the GLP-1 hormone, mimicking it to reduce food intake and appetite. However, Zepbound also initiates a second hormone, GIP, to target how the body digests fat. 

Beyond weight loss, both drugs induce similar gastrointestinal side effects like nausea, diarrhea and stomach pain in mild to moderate severity. 

Additionally, the drugs have proven value beyond treating obesity and diabetes. Wegovy has been shown to reduce the risk of heart disease and Zepbound has been linked as a possible treatment for sleep apnea. 

While Lilly and Novo are considered leaders in the field of obesity drugs, companies like Amgen, Pfizer and Roche are also developing similar style drugs. 

Last week, Amgen released the results of its weight-loss drug MariTide, which not only targets different receptors than Zepbound and Wegovy, but led to less severe side effects. W

hile MariTide was shown to reduce more weight loss than Wegovy, it still fell short in comparison to Zepbound. 

However, the two pharma giants still lead in revenue. 

Wegovy generated around $4.5 billion in sales in 2023 and has been on the market since receiving approval from the Food and Drug Administration in June of 2021. 

Zepbound isn’t too far behind — the drug secured $1.2 billion in its first quarter this year since it hit the market late last year. 

A recent analysis from GlobalData’s Pharma Intelligence Center forecasted that Zepbound will generate approximately $25.5 billion in sales by 2030, while Wegovy is expected to fall short and reach $19.4 billion by the same year. 

Leonard Glass, SVP of global affairs at Lilly, expressed his delight with the study’s results in a statement. He reiterated that Zepbound is currently the only FDA-approval dual GIP and GLP-1 receptor drug targeting obesity, and that the results showed the life changing effects of Zepbound. 

“We are thrilled that today’s findings showed the superior weight loss of Zepbound,” he said.